Stromal Expression of MARCKS Protein in Ovarian Carcinomas Has Unfavorable Prognostic Value by Doghri, Raoudha et al.
HAL Id: hal-02143620
https://hal-amu.archives-ouvertes.fr/hal-02143620
Submitted on 21 Jan 2020
HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.
L’archive ouverte pluridisciplinaire HAL, est
destinée au dépôt et à la diffusion de documents
scientifiques de niveau recherche, publiés ou non,
émanant des établissements d’enseignement et de
recherche français ou étrangers, des laboratoires
publics ou privés.
Distributed under a Creative Commons Attribution| 4.0 International License
Stromal Expression of MARCKS Protein in Ovarian
Carcinomas Has Unfavorable Prognostic Value
Raoudha Doghri, Maroua Manai, Pascal Finetti, Maha Driss, Emilie
Agavnian, Marc Lopez, Meriam Elghardallou, Emmanuelle Charafe-Jauffret,
Mohamed Manai, Max Chaffanet, et al.
To cite this version:
Raoudha Doghri, Maroua Manai, Pascal Finetti, Maha Driss, Emilie Agavnian, et al.. Stromal Expres-
sion of MARCKS Protein in Ovarian Carcinomas Has Unfavorable Prognostic Value. International
Journal of Molecular Sciences, MDPI, 2018, 19 (1), ￿10.3390/ijms19010041￿. ￿hal-02143620￿
 International Journal of 
Molecular Sciences
Article
Stromal Expression of MARCKS Protein in Ovarian
Carcinomas Has Unfavorable Prognostic Value
Raoudha Doghri 1,†, Maroua Manai 1,2,3,†, Pascal Finetti 2, Maha Driss 1,3, Emilie Agavnian 4,
Marc Lopez 2, Meriam Elghardallou 5, Emmanuelle Charafe-Jauffret 4,6, Mohamed Manai 3,
Max Chaffanet 2, Daniel Birnbaum 2, Karima Mrad 1 and François Bertucci 2,6,7,*
1 Département d’Anatomie Pathologique, Institut Salah Azaiez, Bab Saadoun, Tunis 1006, Tunisia;
raoudha.doghri@gmail.com (R.D.); maroua.m@hotmail.com (M.M.); mdriss808@gmail.com (M.D.);
karimamrad@ymail.com (K.M.)
2 Département d’Oncologie Moléculaire, Centre de Recherche en Cancérologie de Marseille, Institut
Paoli-Calmettes, INSERM UMR1068, CNRS UMR7258, Aix-Marseille Université, 13007 Marseille, France;
finettip@ipc.unicancer.fr (P.F.); marc.lopez@inserm.fr (M.L.); chaffanetm@ipc.unicancer.fr (M.C.);
daniel.birnbaum@inserm.fr (D.B.)
3 Département de Biologie, Unité de Biochimie et Biologie Moléculaire, Faculté des Sciences de Tunis,
Université de Tunis El Manar, Tunis 1068, Tunisia; mohamed.manai@fst.rnu.tn
4 Département de Bio-Pathologie, Institut Paoli-Calmettes, 13009 Marseille, France;
agavniane@ipc.unicancer.fr (E.A.); jauffrete@ipc.unicancer.fr (E.C.-J.)
5 Département de Médicine Communautaire, Faculté de Médecine de Sousse, Sousse 4000, Tunisia;
meriamelghardallou@yahoo.fr
6 UFR de Médecine, Aix Marseille Université, 13007 Marseille, France
7 Département d’Oncologie Médicale, Institut Paoli-Calmettes, 13009 Marseille, France
* Correspondence: bertuccif@ipc.unicancer.fr; Tel.: +33-4-9122-3537; Fax: +33-4-9122-3670
† These authors contributed equally and should be considered as first co-authors.
Received: 21 November 2017; Accepted: 21 December 2017; Published: 23 December 2017
Abstract: Epithelial ovarian cancer (EOC) is the most lethal gynecological cancer. Identification of
new therapeutic targets is crucial. MARCKS, myristoylated alanine-rich C-kinase substrate, has
been implicated in aggressiveness of several cancers and MARCKS inhibitors are in development.
Using immunohistochemistry (IHC), we retrospectively assessed MARCKS expression in epithelial
and stromal cells of 118 pre-chemotherapy EOC samples and 40 normal ovarian samples from
patients treated at Salah Azaiez Institute. We compared MARCKS expression in normal versus cancer
samples, and searched for correlations with clinicopathological features, including overall survival
(OS). Seventy-five percent of normal samples showed positive epithelial MARCKS staining versus 50%
of tumor samples (p = 6.02 × 10−3). By contrast, stromal MARCKS expression was more frequent in
tumor samples (77%) than in normal samples (22%; p = 1.41× 10−9). There was no correlation between
epithelial and stromal IHC MARCKS statutes and prognostic clinicopathological features. Stromal
MARCKS expression was correlated with shorter poor OS in uni- and multivariate analyses. Stromal
MARCKS overexpression in tumors might contribute to cancer-associated fibroblasts activation and
to the poor prognosis of EOC, suggesting a potential therapeutic interest of MARCKS inhibition for
targeting the cooperative tumor stroma.
Keywords: epithelial ovarian cancer; immunohistochemistry; MARCKS; prognosis; stroma; survival
1. Introduction
Epithelial ovarian cancer (EOC) is the most lethal gynecological cancer because of often late
diagnosis and high recurrence rate [1]. Despite initial chemosensitivity, ovarian cancer is not
chemocurable. One reason of the high mortality rate is the lack of effective therapeutic options
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in case of chemoresistance. According to the Cancer Registry of Northern Tunisia, EOC is the
second gynecological cancer with an incidence rate of 3.9 per 100,000 inhabitants [2]. It is distributed
into four major pathological types: “serous” (75%), “endometrioid” (10%), “mucinous” (3%), and
“clear cell” (10%), which differ in pathogenesis, molecular alterations, and prognosis [3,4]. The
classical clinicopathological prognostic factors include patient's age, Fédération Internationale de
Gynécologie et d Obstétrique (FIGO) stage, pathological tumor grade and type, and initial surgery
results. Optimal debulking surgery and paclitaxel/platinum-based chemotherapy have improved
survival [5–7]. Nevertheless, the overall 5-year survival rate for patients with EOC is still very low,
approximately 30% [8,9]. In Tunisia, overall survival is 27% at 5-years for advanced-stage EOC [10].
Several molecular subtypes of EOC [11,12] and prognostic gene expression signatures [13,14] have
been reported, but without clinical application to date.
MARCKS, myristoylated alanine-rich C-kinase substrate, a substrate for protein kinase C, is
localized in the plasma membrane and is an actin filament cross-linking protein. Phosphorylation by
protein kinase C or binding to calcium-calmodulin inhibits its association with actin and plasma
membrane, leading to its presence in the cytoplasm. MARCKS plays an important role in the
regulation of cytoskeletal plasticity and especially of actin filaments [15,16]. Ubiquitously expressed in
various tissues [17], it is involved in cell motility, cell adhesion, cytokines secretion [18] phagocytosis,
membrane trafficking [19], and mitogenesis [20]. Many studies have shown the implication of
MARCKS in cancer aggressiveness, notably metastatic process and therapeutic resistance [21–26].
A few studies also demonstrated the efficiency of therapeutic inhibition of MARCKS [27,28]. A
single study of MARCKS expression in EOC has shown that MARCKS is highly expressed in the
ovarian stroma, is required for the differentiation and tumor-promoting function of cancer-associated
fibroblasts (CAFs) and is associated with poor survival [26].
We have here analyzed MARCKS protein expression in stromal and epithelial cells in tumor
samples of patients with EOC treated at Salah Azaiez Institute of Tunis, Tunisia, and searched for
correlations with clinicopathological features and survival. We found more frequent stromal MARCKS
expression in tumor samples (77%) than in normal samples (22%), and correlation with shorter overall
survival in uni- and multivariate analyses, suggesting that MARCKS inhibition might represent a new
therapeutic approach in EOC.
2. Results
2.1. Patients’ Population and Clinicopathological Features
The clinicopathological features of all samples (N = 118) are shown in Table 1. The patients had
a median age of 55 years at diagnosis (range, 27–85). As expected, most of the patients (91%) had
an advanced stage III–VI (FIGO), including 21 cases (18%) with metastasis at diagnosis. The most
frequent pathological type was serous (90%), followed by clear cell carcinoma (4%), mixed (3.5%)
and endometrioid (2.5%). Most of the cases were high-grade (grade 3: 70%). All cases were operated
before or after chemotherapy, with a macroscopic tumor residue in 35% of cases. Adjuvant and/or
neoadjuvant chemotherapy was delivered to 89 patients.
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Table 1. Clinicopathological characteristics of patients.
Characteristics N (%)
Age 55 (27–85)
Pathological type clear cell 5 (4%)
endometrioid 3 (3%)
mixed 4 (3%)
serous 106 (90%)
FIGO Stage 1–2 10 (8%)
3–4 108 (92%)
Pathological grade 1 5 (4%)
2–3 113 (96%)
Surgery no 0 (0%)
yes 118 (100%)
Adjuvant and/or neo-adjuvant chemotherapy no 12 (12%)
yes 89 (88%)
Macroscopic residual disease after surgery no 47 (46%)
yes 55 (54%)
Deaths * 15 (22%)
5-year OS *, [CI95] 35% (22–56)
Median OS, months (range) * 44 (1–172)
* concerns the 68 patients treated with surgery and carboplatin-paclitaxel chemotherapy and with available
follow-up. FIGO: Fédération Internationale de Gynécologie et d Obstétrique; OS: overall survival.
2.2. MARCKS Protein Expression in Epithelial Ovarian Cancer
We first validated the MARCKS antibody using western blot analysis on three breast cancer
cell lines with known MARCKS mRNA expression. As shown in Figure S1, the antibody specifically
recognized MARCKS protein with a good correlation between protein and mRNA expression levels.
MARCKS protein expression was then measured on the 118 tumor samples and 40 normal samples
present on the tissue-microarray (TMA). Examples of staining are shown in Figure 1a and results are
summarized in Figure 1b. Using 1% of stained epithelial cells as positivity cut-off, we found that
75% of normal samples showed positive MARCKS immunostaining versus 50% of tumor samples
(p = 6.02 × 10−3; Fisher’s exact test). Regarding the stroma staining and using the same positivity
cut-off (1% of stained stromal cells), 77% of tumor samples showed positive MARCKS immunostaining
versus 22% of normal samples (p = 1.41 × 10−9; Fisher’s exact test). In tumor samples, the staining
was observed mainly in stromal cells, notably fibroblasts (77% positivity) and to a lesser degree in
tumor epithelial cells (50% positivity; p = 2.37 × 10−5, Fisher’s exact test), whereas in normal tissues,
it was weakly expressed in stromal cells (22% positivity) and more expressed in epithelial cells (75%
positivity; p = 4.85 × 10−6, Fisher’s exact test).
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Figure 1. MARCKS (myristoylated alanine-rich C-kinase substrate) immunostaining in epithelial 
ovarian cancer and normal ovarian samples. (a) Representative images (×200) of stromal MARCKS 
immunohistochemistry (IHC) staining in normal ovary (left top panel: 0% positive cells), and in three 
primary epithelial ovarian cancer (EOC) samples showing different percentages of stained cells score: 
10%, 70%, and 90%; (b) Representative images (×200) of normal ovary with weak expression of 
MARCKS in stromal cells but strong expression in epithelial cells (left) and of primary EOC sample 
with strong expression in stromal fibroblasts and weak expression in epithelial tumor cells (right); (c) 
Box plots showing the percentage of MARCKS-positive (black) samples and MARCKS-negative 
(white) samples (normal, primary tumors) for the epithelial staining (left) and stromal staining 
(right). The p-values are for the Fischer’s exact test. 
Figure 1. MARCKS (myristoylated alanine-rich C-kinase substrate) immunostaining in epithelial
ovarian cancer and normal ovarian samples. (a) Representative images (×200) of stromal MARCKS
immunohistochemistry (IHC) staining in normal ovary (left top panel: 0% positive cells), and in
three primary epithelial ovarian cancer (EOC) samples showing different percentages of stained cells
score: 10%, 70%, and 90%; (b) Representative images (×200) of normal ovary with weak expression of
MARCKS in stromal cells but strong expression in epithelial cells (left) and of primary EOC sample
with strong expression in stromal fibroblasts and weak expression in epithelial tumor cells (right);
(c) Box plots showing the percentage of MARCKS-positive (black) samples and MARCKS-negative
(white) samples (normal, primary tumors) for the epithelial staining (left) and stromal staining (right).
The p-values are for the Fischer’s exact test.
2.3. Correlation of MARCKS Protein Expression with Clinicopathological Features
We analyzed correlations between the binary MARCKS IHC status and prognostic
clinicopathological featu es of sa ple including patients’ ag , FIGO st ge, pathological type and
grade, and macroscopic tumor residue after debulking surgery (Table 2). We did not find any
correlation between epithelial MARCKS expression and clinicopathological features. Similarly, the
stromal IHC status did not correlate with any tested feature. Epithelial and stromal IHC MARCKS
status were not correlated.
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Table 2. Clinicopathological correlations with MARCKS expression (epithelial and stromal).
Characteristics
Epithelial MARCKS IHC Status Stromal MARCKS IHC Status
N Negative(N = 59)
Positive
(N = 59) p-Value N
Negative
(N = 27)
Positive
(N = 91) p-Value
Age 118 54(30–85)
57
(27–79) 0.85 118
57
(27–85)
55
(30–80) 0.171
Pathological type 1 0.847
clear cell 5 2 (3%) 3 (5%) 5 1 (4%) 4 (4%)
endometrioid 3 2 (3%) 1 (2%) 3 0 (0%) 3 (3%)
mixed 4 2 (3%) 2 (3%) 4 0 (0%) 4 (4%)
serous 106 53 (90%) 53 (90%) 106 26 (96%) 80 (88%)
FIGO Stage 0.743 0.694
1–2 10 6 (10%) 4 (7%) 10 3 (11%) 7 (8%)
3–4 108 53 (90%) 55 (93%) 108 24 (89%) 84 (92%)
Pathological
grade 0.226 0.159
1–2 35 21 (36%) 14 (24%) 35 11 (41%) 24 (26%)
3 83 38 (64%) 45 (76%) 83 16 (59%) 67 (74%)
Macroscopic
residual disease
after surgery
0.321 0.213
no 47 21 (40%) 26 (52%) 47 12 (60%) 35 (43%)
yes 55 31 (60%) 24 (48%) 55 8 (40%) 47 (57%)
Epithelial
MARCKS IHC 0.662
negative 59 15 (56%) 44 (48%)
positive 59 12 (44%) 47 (52%)
Stromal
MARCKS IHC 0.662
negative 27 15 (25%) 12 (20%)
positive 91 44 (75%) 47 (80%)
2.4. Correlation of MARCKS Protein Expression with Overall Survival
We then assessed the prognostic value of MARCKS expression for OS in the population of 68
patients treated with surgery and carboplatin-paclitaxel chemotherapy and with available follow-up.
Fifteen of 68 patients (22%) died and the 5-year OS was 35% [95CI 0.22–0.56] (Figure 2a).
In univariate analysis (Table 3), high grade (p = 2.16× 10−2, Wald test; HR = 2.51 [95CI, 1.14–5.49])
and positive stromal MARCKS status (p = 3.77 × 10−2, Wald test; HR = 2.59 [95CI, 1.06–6.36]) were
associated with poor OS, whereas epithelial MARCKS status was not (p = 0.881). In multivariate
analysis (Table 3), the grade remained significant (p = 4.82 × 10−2, Wald test; HR = 2.21 [95CI,
1.01–4.86]), whereas the stromal MARCKS status tended to remain significant (p = 7.90 × 10−2,
Wald test; HR = 2.24 [95CI, 0.91–5.53]).The 5-year OS rate was 28% [95CI 0.15–0.52] in the stromal
MARCKS-positive group versus 53% [0.27–1] in the stromal MARCKS-negative group (p = 3.13× 10−2,
log-rank test; Figure 2b).
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Figure 2. Overall survival in patients with epithelial ovarian cancer. (a) Kaplan-Meier OS curve in 68
patients treated with treated with surgery and carboplatin-paclitaxel chemotherapy and with available
follow-up; (b) Similar to (a), but according to the stromal IHC MARCKS status. The p-value of log-rank
test is indicated.
Table 3. Uni- and multivariate analyses for OS.
Characteristics
Univariate Multivariate
N HR [95CI] p-Value N HR [95CI] p-Value
Age 68 1.02 [0.99–1.05] 0.304
Pathological type endometrioid versusclear cell 68 8.61 [0.74–100] 0.132
mixed versus clear cell 3.00 [0.27–33.7]
serous versus clear cell 1.60 [0.22–11.9]
FIGO Stage 3–4 versus 1–2 68 4.18 [0.54–32.1] 0.169
Pathological grade 3 versus 1–2 68 2.51 [1.14–5.49] 2.16 × 10−2 68 2.21[1.01–4.86] 4.82 × 10
−2
Macroscopic residual
disease after surgery yes versus no 65 1.57 [0.77–3.20] 0.212
Epithelial MARCKS IHC positive versus negative 68 0.95 [0.45–1.97] 0.881
Stromal MARCKS IHC positive versus negative 68 2.59 [1.06–6.36] 3.77 × 10−2 68 2.24[0.91–5.53] 7.90 × 10
−2
3. Discussion
Despite therapeutic progresses achieved during the last decades, the survival of patients with
EOC remains poor, and the identification of new therapeutic targets is crucial. The objective of this
study was to evaluate and compare MARCKS protein expression in stromal and epithelial cells in
a large retrospective series of 118 EOC samples collected from Tunisian patients and to search for
correlations with clinicopathological features. We have shown that MARCKS tumor expression is more
frequent in stromal cells than in epithelial cells, and that stromal MARCKS expression is associated
with shorter overall survival (OS).
We focused on MARCKS protein expression for several reasons: (i) proven role of MARCKS
in cancer progression including metastasis and therapeutic resistance; (ii) ongoing development of
MARCKS inhibitors [27,28]; (iii) commercial availability of a corresponding monoclonal antibody
performing sufficiently well in IHC on paraffin-embedded tissues, as previously reported [26,29].
Before analysis of tissue samples, we revalidated the antibody on cancer cell lines by using western
blot analysis.
MARCKS expression in our series of 118 EOC samples and 40 normal ovarian samples was
heterogeneous in all samples. We found that 75% of normal samples showed positive epithelial
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staining versus 50% of tumor samples. Regarding the stroma staining and with the same positivity
cut-off, 77% of tumor samples showed positive staining versus 22% of normal samples. Because
secretory epithelial cells of the fallopian tubes are the precursors of high-grade serous ovarian tumors,
we analyzed MARCKS expression in 27 samples of normal fallopian tube (Figure S2). Interestingly,
the results were very similar to those observed in the normal ovarian samples for both epithelial (74%
positivity versus 75% in normal ovarian samples) and stromal staining (19% positivity versus 22%).
In tumor samples, the staining was observed mainly in stromal cells, notably fibroblasts, and to a
lesser degree in tumor epithelial cells, whereas in normal tissues, it was weakly expressed in stromal
cells and more expressed in epithelial cells. Thus, MARCKS protein was overexpressed in ovarian
tumor stroma as compared to epithelial cells. In the literature, only one study analyzed MARCKS
protein expression in epithelial ovarian cancer [26] and found similar results. From in silico analyses of
public transcriptional data, the authors first showed that, compared with its expression in the tumor
epithelial compartment, MARCKS was specifically expressed in the stromal compartment. In contrast,
MARCKS level was reduced in the tumor epithelial cells compared with normal ovary epithelial.
Second, using IHC analyses in a small series of 10 normal ovarian tissues and 18 pairs of primary
and metastatic tumors from patients with advanced (stages III–IV) serous adenocarcinoma, they
showed that MARCKS protein was highly expressed in ovarian tumor stroma versus epithelial cells
compartment. Additionally, MARCKS was highly expressed in normal ovary epithelial cells compared
with tumor epithelial cells. We confirmed these results in our present larger study. The authors found
at the transcriptional level in a series of 3431 ovarian cancer specimens a small correlation between
high stroma MARCKS expression and higher FIGO stage. In our series, there was no correlation
between stromal or epithelial protein staining and the classical clinicopathological prognostic features,
including the FIGO stage. Finally and despite the relatively small size of our series (68 informative
cases), we found that stromal MARCKS expression in tumors was associated with shorter OS in
univariate analysis (HR = 2.59), and that such correlation tended towards significance in multivariate
analysis with a hazard ratio equal to 2.24. Such correlation was reported [26], but at the transcriptional
level (but not at the protein level) in terms of progression-free survival and OS. It was suggested
that MARCKS stromal overexpression might contribute to cancer-associated fibroblasts activation in
EOC and explain their therapeutic resistance and unfavorable prognostic impact. In experimental
models, MARCKS overexpression was shown to suppress cellular senescence and boost the activation
of AKT/TWIST1 (Protein kinase B/Twist-related protein 1) signaling to sustain the cancer-associated
fibroblasts features, thus supporting tumor cells growth and invasion.
Several studies in other types of cancers have shown involvement of MARCKS tumor expression
in cancer progression, chemoresistance, and suggested that MARCKS inhibition could be a novel
therapeutic approach. In breast cancer, MARCKS was reported to be implicated in tamoxifen-resistant
MCF7 (Michigan Cancer Foundation-7) breast cancer cells and its inhibition decreased cell motility.
The same study also noted correlations with poor-prognosis features and short OS [29]. More frequent
IHC staining for phospho-MARCKS was found in breast cancer than in normal breast tissue and
correlated with unfavorable prognostic parameters and metastatic status. Using both in vitro and
in vivo models of breast cancer, the p-MARCKS was involved in resistance to paclitaxel treatment,
with an increased paclitaxel sensitivity after reduction of p-MARCKS by knockdown or by treatment
with MANS (p-MARCKS inhibitor peptide targeting the N-terminal myristoylation site) [30]. In
a prior study, we showed that overexpression of MARCKS was correlated with the inflammatory
breast cancer (IBC) phenotype. MARCKS stromal overexpression was more frequent in IBC than in
non-IBC, which could sustain more cancer-associated fibroblasts activation in IBC and higher metastatic
potential. We also showed the unfavorable prognostic value of MARCKS expression for metastasis-free
survival in uni and multivariate analyses [31]. MARCKS was found to have an important role in
the progression of colorectal cancer and to be implicated in cell motility, invasion and proliferation
of colon cancer cells, whereas its inhibition clearly affected these cancer features and reduced the
metastatic events [23]. The metastatic potential of p-MARCKS was shown in melanoma [21]. In
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prostate cancer, MARCKS promoted migration and invasion [32]. In cholangiocarcinoma, MARCKS
overexpression correlated with poor survival, and experimental models showed the role of MARCKS
in the migration of cholangiocarcinoma cells [24]. In a series of 99 patients with squamous cell
lung carcinoma, a correlation was found between protein expression and poor survival [22]. In
another study [28], MARCKS, specifically its phosphorylated form, was a key player in potentiating
lung cancer cell migration/metastasis, suggesting a potential use of MARCKS-inhibition peptides
in the treatment of lung cancer metastasis. Overexpression of p-MARCKS was associated with
unfavorable survival in a series of 195 operated lung cancers and targeting MARCKS phosphorylation
site domain (PSD) with MPS peptide (MARCKS phosphorylation site domain) suppressed tumor
growth, metastasis and increased the sensibility to erlotinib treatment in vivo and in vitro [27]. A recent
study demonstrated that a MARCKS ED peptide inhibited MARCKS phosphorylation, leading to an
increase in sensitivity to radiation therapy [33]. Finally, in kidney cancer, MARCKS inhibition with
MPS peptide synergistically interacted with regorafenib treatment and decreased survival of kidney
cancer cells through inactivation of AKT and mTOR (mechanistic target of rapamycin) [34]. Thus, our
observation of association of stromal MARCKS expression in EOC with shorter OS is consistent with
the clinical and pre-clinical findings published in ovarian cancer and many other cancers.
4. Materials and Methods
4.1. Patients and Samples
We retrospectively collected pre-chemotherapy diagnostic tumor samples from 118 patients with
epithelial ovarian cancer (EOC) treated between 2009 and 2015 at Institute Salah Azaiez of Tunis,
Tunisia. These samples represented the operative specimen for women immediately operated or the
surgical biopsies for women with non-operable disease thus treated with neo-adjuvant chemotherapy.
Main inclusion criteria were pathologically-confirmed EOC, with available formaldehyde-fixed and
paraffin-embedded pre-therapeutic tumor samples, available clinicopathological data, and signed
informed patient’s consent. The control group included 40 normal ovarian tissues from Tunisian
women operated for non-tumor ovarian lesions. All samples were spotted onto a tissue microarray
before IHC analysis. The study was approved by our institutional ethics committee at Institut Salah
Azaiez (N◦ 1646; 15 September 2016).
4.2. Tissue Microarray Construction
One tissue microarray (TMA) was constructed for all 158 cases, as previously described, with
slight modifications [35]. For each sample, two representative tumor areas were carefully selected from
a hematoxylin-eosin stained section of the donor block. Core cylinders with a diameter of 0.6 mm
each were punched from each of these areas and deposited into the recipient paraffin block using a
specific arraying device (Alphelys, Plaisir, France). Four-µm sections were made from the resulting
TMA block, then used for IHC.
4.3. Western Blot Analyses
Before IHC analysis, we validated our MARCKS antibody by using western blot analysis with
breast cancer cell lines. Expression was analyzed in three breast cancer cell lines (T47D, SUM149,
MDA-MB-231) previously profiled using Affymetrix (Thermo Fisher Scientific, Inc., Rockford, IL, USA)
DNA microarrays and for which MARCKS mRNA expression was documented as very low (T47D),
moderate (SUM149), and very high (MDA-MB-231). Cells were washed 3 times with ice-cold PBS
and then resuspended for 30 min in 750 µL of ice cold lysis buffer containing 50 mM Hepes, pH 7.5,
150 mM NaCl, 1.5 mM MgCl2, 1 mM EGTA, 1% Triton X-100, and 10% glycerol. A protease inhibitor
mixture (Pierce, Thermo Fisher Scientific, Inc., Rockford, IL, USA) and the phosphotyrosyl phosphatase
inhibitor sodium orthovanadate (BioLabs Cambridge, MA, USA) were added as recommended. Lysates
were heated in SDS sample buffer (60 mM Tris-HCl, pH 6.7, 3% SDS, 2% (v/v) 2-mercaptoethanol,
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and 5% glycerol), separated by 10% SDS-PAGE, and transferred to nitrocellulose blotting membrane
(Amersham, GE Healthcare Bio-Sciences, Pittsburgh, PA, USA). Membranes were blocked in PBS
supplemented with BSA 5% and tween 0.1% for 1h30 and then incubated overnight at 4 ◦C with
indicated antibodies. Visualization was done with ECL (Pierce, Thermo Fisher Scientific, Inc., Rockford,
IL, USA).
4.4. Immunohistochemistry Analysis
MARCKS protein expression was analyzed on TMA for all 118 EOC and 40 normal ovarian tissues
using standard IHC protocols. Paraffin sections were pretreated in PH6 PT Link (Agilent, Santa Clara,
CA, USA). We used the rabbit monoclonal antibody, anti-MARCKS (D88D11) XP®Rabbit mAb#5607,
from Cell Signaling Technology (dilutionat1/400) for staining and the Flex system (Dako, Agilent,
Santa Clara, CA, USA) using a peroxidase enzyme for antigen revelation. Sections counterstained with
hematoxylin were independently evaluated by two experienced ovarian pathologists (RD and MD)
using light microscopy. Immunostaining scoring of epithelial cancer cells and of stromal cells was
evaluated on the basis of staining intensity and positively stained areas as previously described [31].
MARCKS-negative cases were defined by 0% level expression and positive cases by at least 1%
stained cells.
4.5. Statistical Analysis
Data were summarized by numbers and percentages for categorical variables, and median and
range for continuous variables. Correlations between tumor groups and clinicopathological features
were analyzed using the t-test or the Fisher’s exact test when appropriate. Follow-up was calculated
from the date of diagnosis to the date of last news for event-free patients. Overall survival (OS)
was calculated from the date of diagnosis until the date of death from any cause. Survival was
calculated using the Kaplan-Meier method and curves were compared with the log-rank test. Uni-
and multivariate prognostic analyses for OS were performed using Cox regression analysis (Wald
test). Variables with a p-value ≤ 0.05 in univariate analysis were tested in multivariate analysis. All
statistical tests were two-sided at the 5% level of significance. Analyses were done using the survival
package (version 2.30) in the R software (version 2.9.1; http://www.cran.r-project.org/). We followed
the reporting REcommendations for tumor MARKer prognostic studies (REMARK criteria) [36].
5. Conclusions
We showed MARCKS protein overexpression in the stroma of EOC and its association with
shorter OS. The strengths of our study include the number of cases tested with a total of 118 EOC;
to our knowledge, it is the first study analyzing specifically MARCKS protein expression in a large
series of EOC. Importantly, we highlighted the association of MARCKS protein expression with poor
OS in uni- and multivariate analyses, whereas the only other published study in ovarian cancer
showed the association of MARCKS overexpression with poor OS only at the mRNA level and without
multivariate analysis. Limitations of our study include its retrospective nature and associated biases
such as missing data with the absence of survival information and/or of information about important
prognostic factors such as macroscopic residual disease after surgery for all patients. Our results
suggest that MARCKS overexpression in stromal cells of EOC might contribute to cancer-associated
fibroblasts activation and contribute to the poor prognosis of disease. These findings suggest that
inhibition of MARCKS could be a new potential therapeutic approach in EOC.
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